Neurocrine Biosciences CFO Executes Routine Rule 10b5-1 Stock Sale Following PRSU Vesting
NEUROCRINE BIOSCIENCES INC
Subscribe to track NBIX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
🚨 INSIDER TRANSACTION ALERT
Ticker: NBIX (Neurocrine Biosciences Inc)
Insider: Matt Abernethy (Chief Financial Officer)
Transaction: Sale (Rule 10b5-1)
Shares: 2,311 @ $157.20
Value: $363,284.81
Remaining Holdings: 42,808 shares
Significance: Low (Pre-planned 10b5-1 sale after PRSU vesting)
Comprehensive Analysis
Executive Summary
On September 15, 2026, Neurocrine Biosciences Inc ($NBIX) Chief Financial Officer Matt Abernethy reported the vesting of performance restricted stock units (PRSUs) alongside associated tax withholdings and a pre-planned stock sale under a Rule 10b5-1 trading plan.
Transaction Breakdown
- PRSU Vesting (September 11, 2026):
- Acquisition (Code A): 5,020 shares acquired at $0 per share upon certification of performance metrics.
- Tax Withholding (Code F): 2,709 shares withheld at $156.22 per share ($423,200.00 total) to satisfy mandatory tax obligations.
- Open Market Sale (September 14, 2026):
- Sale (Code S): 2,311 shares sold at a weighted average price of $157.1981 ($363,284.81 total value).
- Trading Plan: Executed under a Rule 10b5-1 plan established on May 22, 2026.
Ownership Post-Transaction
Following these transactions, Matt Abernethy directly holds 42,808 shares of Neurocrine Biosciences common stock.
Market & Trading Significance
The trading significance is assessed as Low. The open market disposition represents routine portfolio management under a pre-scheduled Rule 10b5-1 plan adopted months prior, paired with standard equity compensation vesting and tax withholding.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.